A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Trial Details

NCT ID
NCT07597629
Phase
PHASE2
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • SYS6023
  • KN026
Locations (sample)
  • Harbin, Heilonjiang, China|45.75,126.65

Key Eligibility Criteria

  • 1\. Age ≥ 18 years old;
  • 2\. Histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer:
  • 3\. Sufficient tumor specimens must be provided for biomarker testing (human epidermal growth factor receptor 3-HER3), preferably obtained during o…
  • 4\. Documented disease progression or intolerability with the most recent systemic anti-tumor treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →